Aligos Therapeutics, Inc. APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition
Aligos Therapeutics, Inc. (ALGS) reported APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition of $135.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition · last filed 2026-08-06
- Aligos Therapeutics, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2026-06-30 was $135.00K, a 22.73% increase year-over-year.
- Aligos Therapeutics, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2026-03-31 was $89.00K, a 78.00% increase year-over-year.
- Aligos Therapeutics, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2025-09-30 was $199.00K, a 43.17% increase year-over-year.
- Aligos Therapeutics, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2025-06-30 was $110.00K, a 20.29% decline year-over-year.
- Aligos Therapeutics, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2025 was $503.00K, a 0.20% decline from fiscal 2024.
- Aligos Therapeutics, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2024 was $504.00K, a 40.91% decline from fiscal 2023.
- Aligos Therapeutics, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2023 was $853.00K, a 33.98% decline from fiscal 2022.
- Aligos Therapeutics, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2022 was $1.29M, a 62.52% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $135.00K 10-Q · filed 2026-08-06 | $224.00K derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $89.00K 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $503.00K 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $199.00K 10-Q · filed 2025-11-06 | $309.00K derived: sum of 2 quarters · filed 2026-08-06 | $359.00K derived: sum of 3 quarters · filed 2026-08-06 | $437.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $110.00K 10-Q · filed 2026-08-06 | $160.00K derived: sum of 2 quarters · filed 2026-08-06 | $238.00K derived: sum of 3 quarters · filed 2026-08-06 | $377.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $50.00K 10-Q · filed 2026-08-06 | $128.00K derived: sum of 2 quarters · filed 2026-08-06 | $267.00K derived: sum of 3 quarters · filed 2026-08-06 | $405.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2024-12-31 | $78.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $217.00K derived: sum of 2 quarters · filed 2026-03-05 | $355.00K derived: sum of 3 quarters · filed 2026-03-05 | $504.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $139.00K 10-Q · filed 2025-11-06 | $277.00K derived: sum of 2 quarters · filed 2025-11-06 | $426.00K 10-Q · filed 2024-11-06 | $570.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $138.00K 10-Q · filed 2025-11-06 | $287.00K 10-Q · filed 2024-08-06 | $431.00K derived: sum of 3 quarters · filed 2025-11-06 | $757.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-03-31 | $148.00K 10-Q · filed 2025-11-06 | $293.00K derived: sum of 2 quarters · filed 2025-11-06 | $619.00K derived: sum of 3 quarters · filed 2025-11-06 | $841.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2023-12-31 | $145.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $471.00K derived: sum of 2 quarters · filed 2025-03-10 | $693.00K derived: sum of 3 quarters · filed 2025-03-10 | $853.00K 10-K · filed 2025-03-10 |
| 2023-09-30 | $326.00K 10-Q · filed 2024-11-06 | $548.00K derived: sum of 2 quarters · filed 2024-11-06 | $708.00K 10-Q · filed 2024-11-06 | $891.00K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $222.00K 10-Q · filed 2024-08-06 | $382.00K 10-Q · filed 2024-08-06 | $565.00K derived: sum of 3 quarters · filed 2024-08-06 | $784.00K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $161.00K 10-Q · filed 2024-05-07 | $343.00K derived: sum of 2 quarters · filed 2024-05-07 | $562.00K derived: sum of 3 quarters · filed 2024-05-07 | $1.01M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $182.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $401.00K derived: sum of 2 quarters · filed 2024-03-12 | $848.00K derived: sum of 3 quarters · filed 2024-03-12 | $1.29M 10-K · filed 2024-03-12 |
| 2022-09-30 | $219.00K 10-Q · filed 2023-11-02 | $666.00K derived: sum of 2 quarters · filed 2023-11-02 | $1.11M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $447.00K 10-Q · filed 2023-08-03 | $891.00K 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $444.00K 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $795.00K 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |